Zhang Yaping, You Xuefen, Liu Hong, Xu Mengqi, Dang Qingxiu, Yang Li, Huang Jianfei, Shi Wenyu
Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Clinical biological sample library, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Ann Hematol. 2017 Sep;96(9):1485-1491. doi: 10.1007/s00277-017-3047-1. Epub 2017 Jun 14.
Kinesin family member 2A (KIF2A), a conserved motor protein, plays a critical role in the pathogenesis and prognosis of several malignant tumors. The aim of the present study was to investigate KIF2A expression in diffuse large B cell lymphoma (DLBCL), evaluate the association between KIF2A expression and the clinical parameters of the disease, and determine its prognostic value. KIF2A expression was evaluated in 134 DLBCL and 57 reactive hyperplasia samples using immunohistochemistry on a tissue microarray. The correlations between KIF2A expression with clinical parameters and prognosis were estimated using univariate and multivariate analyses. The expression of KIF2A was significantly higher in DLBCL tissue samples compared with those from subjects with reactive hyperplasia (P=0.002). Furthermore, increased expression of KIF2A protein in DLBCL was related to Ann Arbor stage (P=0.027) and international prognostic index (IPI) score (P=0.01). The survival analysis showed that KIF2A expression (P=0.016), serum LDH level (P=0.049), and IPI score (P<0.001) were independent prognostic markers for DLBCL. Our findings also confirmed that downregulating KIF2A expression decreased tumor cell viability, accompanied by downregulation of pAKT levels. Taken together, these data provide the first evidence that increased KIF2A expression predicts poor prognosis in patients with DLBCL, and a rationale for treatment of DLBCL by targeting KIF2A.
驱动蛋白家族成员2A（KIF2A）是一种保守的运动蛋白，在多种恶性肿瘤的发病机制和预后中起关键作用。本研究旨在调查KIF2A在弥漫性大B细胞淋巴瘤（DLBCL）中的表达，评估KIF2A表达与该疾病临床参数之间的关联，并确定其预后价值。在组织芯片上使用免疫组织化学方法对134例DLBCL样本和57例反应性增生样本中的KIF2A表达进行评估。使用单因素和多因素分析评估KIF2A表达与临床参数和预后之间的相关性。与反应性增生患者的组织样本相比，DLBCL组织样本中KIF2A的表达显著更高（P = 0.002）。此外，DLBCL中KIF2A蛋白表达的增加与Ann Arbor分期（P = 0.027）和国际预后指数（IPI）评分（P = 0.01）相关。生存分析表明，KIF2A表达（P = 0.016）、血清乳酸脱氢酶水平（P = 0.049）和IPI评分（P<0.001）是DLBCL的独立预后标志物。我们的研究结果还证实，下调KIF2A表达会降低肿瘤细胞活力，同时伴随着pAKT水平的下调。综上所述，这些数据首次证明KIF2A表达增加预示着DLBCL患者预后不良，并为通过靶向KIF2A治疗DLBCL提供了理论依据。
